Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

被引：83

作者：

Alphandery, Edouard ^{[1
,2
]}

Grand-Dewyse, Pierre ^{[1
]}

Lefevre, Raphael ^{[1
,3
]}

Mandawala, Chalani ^{[1
,4
]}

Durand-Dubief, Mickael ^{[1
]}

机构：

[1] Nanobacterie Inc, 36 Blvd Flandrin, F-75116 Paris, France

[2] Univ Paris 06, IMPMC, F-75252 Paris, France

[3] Inst Phys Globe Paris, F-75238 Paris 05, France

[4] Museum Natl Hist Nat, IMPMC, F-75252 Paris, France

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 10期

关键词：

cancer; nanodrug; nanoformulated drug; nanoformulation; nanomedicine; nanooncology; nanoparticle; nanopharmaceuticals; LIPOSOME-ENCAPSULATED DOXORUBICIN; AMB-1 MAGNETOTACTIC BACTERIA; TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; ALBUMIN-BOUND PACLITAXEL; PHASE I/II TRIAL; MAGNETIC NANOPARTICLES; DAUNORUBICIN DAUNOXOME; COLLOIDAL GOLD; CONVENTIONAL DOXORUBICIN;

D O I：

10.1586/14737140.2015.1086647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several of these substances such as Marqibo, Myocet, Doxil, DaunoXome, MM398, MM302, Mepact, Versamune, Thermodox, Depocyt, Livatag, Abraxane, Eligard, Opaxio, Zinostatin Stimalamer (SMANCS), Pegasys and PegIntron, BIND-014, CRLX-101, Oncaspar, Neulasta, Aurimmune, Auroshell, AuNPs, Nanotherm, NanoXray, Magnetosome chains, Kadcyla (T-DM1), Ontak (DAB/IL2), Gendicine and Curcumin. We describe their specific properties, such as their stability, solubility, mean of administration or targeting, distribution, metabolism and toxicity. We discuss their categorization as medical devices or drugs, their fabrication process within a regulatory environment as well as intellectual property and financial aspects that are all essential to enable their industrial development.

引用

页码：1233 / 1255

页数：23

共 143 条

[11] A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer [J].

Amadori, D. ;

Milandri, C. ;

Comella, G. ;

Saracchini, S. ;

Salvagni, S. ;

Barone, C. ;

Bordonaro, R. ;

Gebbia, V. ;

Barbato, A. ;

Serra, P. ;

Gattuso, D. ;

Nanni, O. ;

Baconnet, B. ;

Gasparini, G. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) :2091-2098

[12] Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma [J].

Ansell, S. M. ;

Tang, H. ;

Kurtin, P. J. ;

Koenig, P. A. ;

Nowakowski, G. S. ;

Nikcevich, D. A. ;

Nelson, G. D. ;

Yang, Z. ;

Grote, D. M. ;

Ziesmer, S. C. ;

Silberstein, P. T. ;

Erlichman, C. ;

Witzig, T. E. .

LEUKEMIA, 2012, 26 (05) :1046-1052

[13] Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo [J].

Bardhan, Rizia ;

Chen, Wenxue ;

Bartels, Marc ;

Perez-Torres, Carlos ;

Botero, Maria F. ;

McAninch, Robin Ward ;

Contreras, Alejandro ;

Schiff, Rachel ;

Pautler, Robia G. ;

Halas, Naomi J. ;

Joshi, Amit .

NANO LETTERS, 2010, 10 (12) :4920-4928

[14] Doxil® - The first FDA-approved nano-drug: Lessons learned [J].

Barenholz, Yechezkel .

JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134

[15] Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].

Batist, G ;

Ramakrishnan, G ;

Rao, CS ;

Chandrasekharan, A ;

Gutheil, J ;

Guthrie, T ;

Shah, P ;

Khojasteh, A ;

Nair, MK ;

Hoelzer, K ;

Tkaczuk, K ;

Park, YC ;

Lee, LW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454

[16] Emerging nanopharmaceuticals [J].

Bawarski, Willie E. ;

Chidlowsky, Elena ;

Bharali, Dhruba J. ;

Mousa, Shaker A. .

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2008, 4 (04) :273-282

[17]

Bosetti R, 2011, NANOMEDICINE-UK, V6, P747, DOI [10.2217/nnm.11.55, 10.2217/NNM.11.55]

[18] Efficacy and tolerability of 1-and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study [J].

Braeckman, Johan ;

Michielsen, Dirk .

ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (03) :477-483

[19] Tumor necrosis factor-α augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (DOXIL®) correlates with altered DOXIL® pharmacokinetics [J].

Brouckaert, P ;

Takahashi, N ;

Van Tiel, ST ;

Hostens, J ;

Eggermont, AMM ;

Seynhaeve, ALB ;

Fiers, W ;

Ten Hagen, TLM .

INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) :442-448

[20] Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXomeA®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients [J].

Camera, Andrea ;

Rinaldi, Ciro R. ;

Palmieri, Salvatore ;

Cantore, Nicola ;

Mele, Giuseppina ;

Mettivier, Vincenzo ;

Miraglia, Eustachio ;

Mastrullo, Lucia ;

Grimaldi, Francesco ;

Luciano, Luigia ;

Guerriero, Anna ;

Rotoli, Bruno ;

Ferrara, Felicetto .

ANNALS OF HEMATOLOGY, 2009, 88 (02) :151-158

← 1 2 3 4 5 6 7 8 9 10 →